Aspira Women's Health Inc. announced it has signed an exclusive licensing agreement with the Dana-Farber Cancer Institute ("DFCI") for the design and development of a new noninvasive miRNA-based ovarian cancer diagnostic tool. The new test will utilize circulating microRNAs, either alone or in conjunction with proteins or other factors, to identify ovarian cancer in women with adnexal masses. It will be offered to healthcare providers as an expansion of the Company's OvaSuite porfolio.

The new test will utilize a proprietary DFCI microRNA ovarian cancer signature in conjunction with Aspira's proprietary AI/machine learning algorithms to assess ovarian cancer risk. Micro-RNAs, a type of RNA that originates in the cell nucleus with a small amount leaking into the bloodstream, are easily isolated from the blood and can be amplified for detection with PCR-based or next generation sequencing technologies. The agreement is in addition to the current sponsored research agreement between Aspira and a consortium of institutions led by DCFI for the development of a noninvasive test to aid in the detection of endometriosis using circulating microRNAs and proteins.